BioNTech (BNTX) AI Day 2024 summary

Strategic Vision and AI Integration

• Focus on building an AI-first, personalized immunotherapy platform, leveraging expertise in AI, genomics, and life sciences to accelerate individualized treatment development and drug discovery.

• InstaDeep operates as a wholly owned subsidiary, maintaining a dual focus on internal BioNTech projects and external third-party business, with AI embedded across R&D, manufacturing, and tailored immunotherapies.

• The partnership addresses cancer treatment failure due to interindividual variability and intratumoral heterogeneity, integrating multiple therapeutic modalities including mRNA vaccines and immunomodulators.

• AI and digital integration are central to target and drug discovery, manufacturing, and the development of potentially curative approaches.

• InstaDeep and BioNTech have developed the Kyber exascale supercomputing cluster in Paris, providing over 200 NVIDIA H100 GPUs and 86,000 CPUs, ranking among the top 100 global computing infrastructures.

Scaling AI Capabilities and Model Innovation

• The Kyber cluster enables 10x more compute power, supporting large-scale AI model training, advanced research in digital biology, and rapid scaling of AI workloads.

• InstaDeep introduced Bayesian Flow Networks (BFN), including ProtBFN and AbBFN, for high-fidelity, diverse protein sequence generation, outperforming existing models.

• The AbBFNX model enables multimodal antibody design, modeling 36 data modalities for flexible, conditional generation in diverse therapeutic scenarios.

• Foundation models for genomics, such as Nucleotide Transformer and SegmentNT, deliver state-of-the-art performance in genome annotation and splicing detection, widely adopted in the research community.

• InstaNovo, a deep learning-based de novo peptide sequencing tool, increases immunopeptidomics data set coverage by 40%, supporting novel target discovery for cancer immunotherapies.

AI Platforms, Business Strategy, and External Engagement

• DeepChain platform integrates flagship generative models, enabling de novo antibody design, genomics analysis, and model fine-tuning, accessible both internally and externally.

• DeepChain and open-source models are available for external partners, while proprietary data and applications remain protected for competitive advantage.

• InstaDeep balances internal deployment with selective external commercialization, ensuring data privacy and tailored solutions for different stakeholders.

• InstaDeep continues to publish research and collaborate with academic and industry partners, maintaining a leading position in AI innovation.

• AI-driven automation, such as the Layla agent, is being integrated into lab operations, improving transparency, error handling, and operational efficiency.